Frontiers in Immunology· 2020Q1
Isolated Nocardiosis, an Unrecognized Primary Immunodeficiency?
- 73citations
- Q1SCImago
- 2020year
Short summary
A review of 30 years of literature suggests that isolated nocardiosis, occurring in individuals without apparent risk factors, may indicate an undiagnosed primary immunodeficiency (PID).
AI-generated from the title and abstract; the full text is not read.
Key points
- Nocardiosis typically affects immunocompromised individuals, but cases are increasing in those without known risk factors.
- Undiagnosed primary immunodeficiencies (PIDs) are proposed as a potential cause for isolated nocardiosis.
- The review covers 30 years of clinical and microbiological data on isolated nocardiosis.
- It also examines human immune responses to Nocardia spp. informed by PID research.
AI-generated from the title and abstract; the full text is not read.
Abstract
Nocardiosis is an infectious disease caused by the Gram-positive bacterium Nocardia spp. Although it is commonly accepted that exposure to Nocardia is almost universal, only a small fraction of exposed individuals develop the disease, while the vast majority remain healthy. Nocardiosis has been described as an “opportunistic” disease of immunocompromised patients, suggesting that exposure to the pathogen is necessary, but a host predisposition is also required. Interestingly, increasing numbers of nocardiosis cases in individuals without any detected risk factors, i.e., without overt immunodeficiency, are being reported. Furthermore, a growing number of evidence have shown that selective susceptibility to a given pathogen can be caused by primary immunodeficiency (PID). This raises the question of whether an undiagnosed PID may cause nocardiosis affecting otherwise healthy individuals. This review summarizes the specific clinical and microbiological characteristics of patients with isolated nocardiosis published during the past 30 years. Furthermore, it gives an overview of the known human immune mechanisms to fend off Nocardiosis spp. obtained from the study of PIDs and patients under immunomodulatory therapies.
The authors' abstract, as published at the source. Frontiers in Immunology, 2020 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Microbiology
MicrobiologyMedicine